
A November 5 headline asks whether an earnings beat changed Gilead Sciences’ investment narrative. But the supplied information doesn’t include the earnings results, the size of the beat, or management’s comments, so it’s not possible to assess the headline’s premise. Gilead’s latest listed close was US$167.47.
Investor takeaway: The headline points to an earnings beat, but without results or comparison figures, its significance for Gilead Sciences remains unclear.
US$167.47 latest close
Gilead Sciences Inc
GILD.US
GILD.US
Gilead Sciences Inc
Market cap
$216.41B
Div. yield
1.94%
Div. / share
$3.25
52W high
$176.58
52W low
$114.31
1W change
+9.60%
Beta
0.37
Analyst Price Targets
Based on 28 analysts covering GILD · as of Nov 4, 2026
Wall Street analysts forecast GILD stock price to rise 2.9% over the next 12 months.
Consensus
Buy4.32 / 5.00
Avg. Target
C$172.50
+2.9% Upside
Previously C$170.88 on Nov 2, 2026
Current Price
C$167.57
Last close
Analyst Breakdown (28 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GILD's historical volatility
30-Day Vol
32.4%
Annualized
90-Day Vol
29.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$200.33
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$177.85 | C$159.02 – C$198.90 |
| 60 trading days | C$188.75 | C$161.13 – C$221.11 |
| 90 trading days | C$200.33 | C$165.04 – C$243.17 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Gilead closed at US$167.47, up 4.19% for the day. Trading volume was 496,640 shares, compared with a 20-day average of 6,777,390.
Bull case
Gilead shares closed at US$167.47, up 4.19% in one day and 20.64% in one month. The supplied headline also raises the possibility that an earnings beat changed the investment narrative.
Bear case
The supplied information doesn’t include earnings, revenue, guidance, or the size of the beat. Trading volume was 496,640 shares, below the 20-day average of 6,777,390.
What happened: an earnings beat is raised as a question
The November 5 headline asks, “Did Earnings Beat Just Shift Gilead Sciences’ (GILD) Investment Narrative?” The supplied information doesn’t include the earnings release, reported results, consensus estimates, or management’s explanation. So the headline identifies the topic, but doesn’t show how large the beat was or whether the company’s outlook changed. Gilead also issued a separate November 5 headline about positive Phase 3 IDEAL study results for Livdelzi. That’s a distinct event and doesn’t provide evidence about the earnings beat. For company information, see the Gilead Sciences stock page.
What the numbers show: a US$167.47 close
Gilead’s latest listed close was US$167.47. Shares rose 4.19% in one day, 9.60% in one week, and 20.64% in one month. The supplied year-to-date change was 46.07%. Trading volume was 496,640 shares, compared with a 20-day average of 6,777,390 shares. The supplied facts also report volume at 1.68 times the average. The stock’s 52-week range was US$114.31 to US$176.58, and the close was at 85% of that range. These figures describe trading, but don’t show whether the earnings beat drove the share-price moves. The GILD.US stock page lists the company profile.
What to watch next: the missing earnings details
To assess the headline, you’d need Gilead’s actual earnings and revenue, how they compared with expectations, and any updated guidance or management comments. Without those details, it’s not possible to tell whether the beat reflects a change in business performance or shifts the investment narrative. The supplied facts also report negative trailing-twelve-month EPS of -3.13 and a profit margin of -12.5%, but don’t explain how those figures relate to the earnings event. Any assessment should stay limited to the headline and the available price and volume data.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.

Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.


